ASSET PURCHASE AGREEMENT by and among BLACKBIRD BIOFINANCE, LLC, as Seller, DR. SCOTT ANTONIA and SAM SHRIVASTAVA as Principals, CELLULAR BIOMEDICINE GROUP, INC. as Parent, CELLULAR BIOMEDICINE GROUP VAX, INC. as Buyer Dated as of June 8, 2015Asset Purchase Agreement • July 2nd, 2015 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 2nd, 2015 Company Industry JurisdictionThis ASSET PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of June 8, 2015, by and among Blackbird BioFinance, LLC, a Ohio limited liability company (“Seller”), Dr. Scott Antonia (“Antonia”), Sam Shrivastava (“Shrivastava” and together with Antonia, the “Principals”), Cellular Biomedicine Group, Inc., a Delaware corporation (“Parent”), and Cellular Biomedicine Group Vax, Inc., a California corporation and a wholly-owned subsidiary of Parent (“Buyer”).
ASSET PURCHASE AGREEMENT by and among BLACKBIRD BIOFINANCE, LLC, as Seller, DR. SCOTT ANTONIA and SAM SHRIVASTAVA as Principals, CELLULAR BIOMEDICINE GROUP, INC. as Parent, CELLULAR BIOMEDICINE GROUP VAX, INC. as Buyer Dated as of June 8, 2015Asset Purchase Agreement • June 12th, 2015 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 12th, 2015 Company Industry JurisdictionThis ASSET PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of June 8, 2015, by and among Blackbird BioFinance, LLC, a Ohio limited liability company (“Seller”), Dr. Scott Antonia (“Antonia”), Sam Shrivastava (“Shrivastava” and together with Antonia, the “Principals”), Cellular Biomedicine Group, Inc., a Delaware corporation (“Parent”), and Cellular Biomedicine Group Vax, Inc., a California corporation and a wholly-owned subsidiary of Parent (“Buyer”).